摘要
目的分析探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效。方法以我院2014年9月—2016年6月的80例冠心病心力衰竭患者为对象。通过随机分组的方法将80例患者分为观察组和对照组,各40例。观察组患者采用美托洛尔联合曲美他嗪进行治疗,对照组患者采用曲美他嗪进行常规处理,观察和对比观察组和对照组的冠心病心力衰竭患者经治疗后,临床上心脏功能中恢复及治疗情况,分析联合治疗效果。结果经临床调查发现:观察组总有效率(97.5%,39/40)明显高于对照组的(52.5%,21/40),差异显著(P<0.05)。观察组治疗后LVEDD、LVEF、LVESD等各方面均优于对照组,差异显著(P<0.05)。结论美托洛尔联合曲美他嗪对于治疗冠心病心力衰竭临有着明显的优势,临床治疗效果显著,缓解不适感,值得临床推广。
Objective： To analyze the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods： In our hospital,Eighty cases of cardiac failurepatients with coronary heart disease（ CHD） were selected as the targetin September 2014—June 2016. Eighty patientswererandomlyandaveragelydividedintoobservation groupandthecontrol. The observation group were treated with Metoprolol and Trimetazidine,the control group were Trimetazidine for routine treatment. Observation and comparison of the observation group and the control group of coronary heart disease patients with cardiac failureafter the treatment,the clinical heart function recovery and treatment,analysis of the combined therapeutic effect. Results： The clinical survey showed that the total effective rate of theobservation group（ 98. 3%,59/60） was significantly higher than the control group（ 68. 3%,41/60）,significant difference（ P〈0. 05）. The LVEDD,LVEF and LVESD in the observation group were better than those in thecontrol group,significant difference（ P〈0. 05）. Conclusion： Metoprolol combined with trimetazidine has obvious advantages in the treatment of coronary heart disease and heart failure. It has obvious clinical effect and relieving discomfort. It is worthy of clinical promotion.
作者
陈岳彪
CHEN Yue-biao(Leizhou People＇s Hospital,Leizhou 524200,China)
出处
《泰山医学院学报》
CAS
2018年第6期650-652,共3页
Journal of Taishan Medical College
关键词
美托洛尔
曲美他嗪
冠心病
心力衰竭
metoprolol
Trimetazidine
coronary disease
cardiac failure
